Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, agreed to merge with Homology Medicines, a clinical-stage genetic medicines company historically focused on transforming the lives of patients suffering from rare diseases. "Following a comprehensive assessment of our strategic options, management and the Board of Directors believe the merger with Q32 Bio is in the best interest of our shareholders. The Q32 Bio management team's extensive track record, deep biopharmaceutical expertise and the potential of its clinical development pipeline provide a compelling opportunity to deliver meaningful treatments to patients with critical unmet needs," Albert Seymour, Homology Medicines President and CEO.